Navigation Links
EYESI Ophthalmosurgical Simulator

ProductsEYESI Ophthalmosurgical Simulator
Company VRmagic GmbH
Item EYESI Ophthalmosurgical Simulator
Features Basic Training Module 1

Navigation (needle*): Training of precise navigation with surgical instruments viewed under the stereo microscope.

Object manipulation (tweezers*): Using tweezers to manipulate solid objects in the vitreous body and to remove objects from the vitreous body.

Vitrectomy (vitrectomy unit*): Learning how to use the vitrectomy unit correctly and how to regulate the cutting speed and flow or suction. * Every chapter also includes simulation of the surgery lamp.

Membrane Simulation Module
Simulation equipment included in the module:

  • Various intraocular membranes need to be removed.
  • The vitrectomy unit and a variety of light sources, tweezers, hooks and scissors are available.
  • Vitrectomy unit, configurable for flow or vacuum control
  • Monitoring and display of retina and lens injuries
  • Microscope control by pedal, configurable pedal for control of equipment and instruments
Description EYESI is a simulator for intraocular surgery. The use of advanced computer technology gives the surgeon the feeling that he is experiencing real intraocular surgery. During simulated surgery the surgeon uses instruments that feel and function just like the real ones. The view through the EYESI microscope is similar to the familiar stereo vision through the surgical microscope. The course of surgery is not predefined but is dependent on the way the surgeon works. Tissue reaction is individually computed in each training session. The system is intuitively controlled through a touch display. EYESI allows you to experience intraocular surgery realistically outside the operating room.

Ophthalmosurgical training It takes a long time to gain broad experience. The learning process, in particular the handling of complications, is limited by the number of cases in hospitals. Wetlab training is only realistic to a certain extent. Beginners can only gain surgical experience on patients, thus increasing the risk of complications. The lack of routine in treating rare cases can make it necessary to refer patients to specialized hospitals. It is difficult to produce objective documentation of training successes and surgical ability.

Optimization potential An ideal training system generates realistic surgery situations and enables trainee surgeons to get familiar with standard surgery procedures as well as the treatment of rare cases and complications. The handling of new surgical instruments and the use of new surgical procedures can be practiced without any risk for the patient. The surgical ability of trainee doctors can be tested and assessed objectively. The training method is available at any time and without any effort.

The next step in training, teaching and instruction
Training with EYESI is realistic and is not on patients. The risk of complications inherent in conventional practical training is reduced to a minimum. With its autodidactic training methods and easy accessibility EYESI offers significantly better efficiency in training and further training. Reproducibility and documentation options ensure that surgical abilities are assessed objectively. EYESI enables optimum preparation in the use of new instruments, equipment and surgical techniques. Surgery with EYESI is fun.

Info VRmagic GmbH
Customer Service: +49 (0) 621 / 400 416 - 0
Web site: http://www.vrmagic.com/index_e.html

Related medicine products :

1. Clearview H. pylori II
2. Clearview Chlamydia
3. Clearview Mono-plus II
4. Clearview hCG Combo
5. Clearview hCG Urine II -- Dipstick
6. Clearview hCG Combo w/ Reference Line
7. Clearview hCG Urine II -- Cassette
8. Clearview C DIFF A
9. Clearview Troponin I
10. Clearview Exact Influenza A & B
11. Clearview hCG II - Urine Cassette
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes.
...aspiration holes and additional electrode tip insu...recise dissection with decreased risk of collatera... design options allow the choice between retractab...designs. Optimize specific surgical demands safely...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Medicine Products:
(Date:12/3/2008)... Dec. 3 Ten students pu...sey will receive $5,000 and $2,000 scholarships fr...at the Fifth Annual Hispanic Health Professional S... New York Marriott Marquis Hotel. , , The ... Foundation, who donated $15,000 for $5,000 awards...
(Date:12/3/2008)...E, R.I., Dec. 3 Blue Cross & B...England (CNE) today announced that they have,reac...CNE will remain in the,BCBSRI network until 2013....,Women & Infants, and Butler) and the VNA of...esident and CEO James E. Purcell, "These are,chal...
(Date:12/3/2008)...Dec. 3 A patient who was surgicall... product, for an off-label use promoted,by Medtro...ling, according to,James A. Dunlap Jr. & Asso...it,in California along with another national law ...things, that Medtronic improperly,promoted its In...
(Date:12/3/2008)...dy suggests the procedure impairs healthy immune r... News) -- Children born by Caesarean section are a...earchers, who conducted long-term monitoring of th... By the time they were 8 years old, 362 (12.4 perc...a for which they,d been prescribed inhaled steroid...
Breaking Medicine News(10 mins):Health News:NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals 2Health News:Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:C-Section Might Boost Baby's Asthma Risk 2
...s than the standard weight seem to be at significa...ndrome or IBS, suggests research published// ahead...rs base their findings on 3334 twin pairs, 1250 of...eted a comprehensive questionnaire about their hea...
...e University of Virginia (UVa) and Reckitt-Benckis... is all very easy thanks // to the amount of viral... study was presented at the annual Interscience Co...hemotherapy (ICAAC). During daily activities, adul...
...student of the premier All India Institute of Medi...even as authorities // said measures were being ta...ampus. Kamal Raj Kiran was admitted in a special w...ive for dengue Thursday. His condition deteriorate...
...that prices of 200 brand name drugs which are take...during the 12 month period ending // mid June 2006...s conducted by AARP and reported in their Rx Watch... also reported that the prices of 75 commonly used...
Other Medicine News:Health News:Restricted Fetal Growth Increases Risk of Irritable Bowel Syndrome 2Health News:Common Cold All Too Easy To Catch 2Health News:Common Cold All Too Easy To Catch 3Health News:Common Cold All Too Easy To Catch 4Health News:AIIMS Student Dies of Dengue Fever 2Health News:Brand Name Drug Prices Zoom 2
(Date:12/3/2008)...swire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI...ompany,s,manufacturing and control process descri...onovo can move forward with the development of Men...ashes. , "We have concluded three CMC discu...e Agency,s recommendations for further development...
(Date:12/2/2008)... -- IBT Laboratories, a leading clinical-diagnost...g in immunology and allergy assays, announced that...nse of patients whose immune systems may be compro...chemotherapy drugs, or because they are taking imm...ansplant. The company launched the two new assays,...
(Date:12/1/2008)... A study has found that...que for imaging the breast, is not affected by eit...wo factors that limit the effectiveness of standar... will be presented today at the annual meeting of ... , , "The ability of PEM to detect cancer d...
(Date:12/1/2008)...reated With ENB-0040 at Children,s Hospital, Healt... Dec. 1 Enobia Pharma, an emerging...vel therapeutics for serious bone disorders, today...inical program for hypophosphatasia was dosed. Eno...RT) with ENB-0040 for the treatment of this rare a...
Breaking Medicine Technology:Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 1Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 2Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 21289 3ChanTest Launches Redesigned Web Site 5877 1ChanTest Launches Redesigned Web Site 5877 2Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 1Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 2Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 3Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 4Raptor Pharmaceuticals Corp Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease 5875 5LMXonline Offers Spanish Language Safety and Health Training Library 5873 1LMXonline Offers Spanish Language Safety and Health Training Library 5873 2
...unces Positive Top-Line Phase III Results for,Kepp...izures in,Paediatric Patients from One Month to Le...ril 20, 2007 - UCB today announced,positive top-li...zed, multi-centre, placebo-controlled study evalua...(levetiracetam) (20-50,mg/kg/day) as adjunctive th...
...dy Demonstrated the Clinical Potential of Peregrin...ere as Effective as,Avastin(R) in Animal Cancer Mo...irstCall/ --,Peregrine Pharmaceuticals, Inc. , a c... targeted monoclonal antibodies,for the treatment ...eported that data from multiple studies presented ...
Other Medicine Technology:UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7